Pharma services: CDMOs, CROs, and market access

The seventh sub-sector: healthcare services without a patient in sight

Every biopharma company faces the same problem before it ever gets a drug approved: it needs to manufacture the compound at scale, run clinical trials on real patients, and eventually navigate pricing and coverage with payors, and very few companies want to build every one of those capabilities in-house. Pharma services is the sub-sector that grew up to fill that gap, and it's worth treating as its own category rather than folding it into biopharma, because its customers, revenue model, and valuation logic are genuinely different from the sponsors it serves.

This article covers what the sub-sector actually does, why sponsors and financial buyers both find the model attractive, and how to frame its valuation without borrowing biopharma's risk-adjusted toolkit by mistake. For where pharma services sits relative to the rest of healthcare, see the healthcare sub-sector map.

What CDMOs, CROs, and market-access firms actually do

A contract development and manufacturing organization, shortened to CDMO, manufactures drug substance or finished dosage product on behalf of a sponsor. A small biotech with a promising molecule and no manufacturing footprint of its own can hire a CDMO to produce clinical-trial material and, later, commercial-scale supply, without ever building a plant. Even large, fully integrated pharma companies use CDMOs selectively, for overflow capacity, for specialized manufacturing processes they don't want to build in-house, or for a new modality that doesn't fit their existing footprint.

A contract research organization, or CRO, runs clinical trials for a sponsor. That covers a wide range of work: designing the trial protocol, recruiting and managing patient sites, collecting and managing trial data, and preparing the regulatory submission package. Running a global trial is a logistics and data-management undertaking as much as a scientific one, and most sponsors, even large pharma companies with in-house clinical teams, outsource a meaningful share of trial execution to a CRO rather than staffing every trial internally.

Around those two anchor categories sits a broader set of commercialization services: medical affairs support, which helps a sponsor communicate clinical data to physicians once a drug is approved; patient access and market-access consulting, which helps a sponsor navigate pricing and payor coverage decisions before and after launch; and site management organizations, which operate clinical trial sites on a sponsor's behalf. All of it exists for the same underlying reason: a sponsor's real, differentiated value sits in the molecule and the science behind it, not in operating a manufacturing plant or running trial logistics, so it makes economic sense to buy those capabilities as a service rather than build them.

Why sponsors, and buyers, like the model

For a sponsor, the appeal is straightforward: outsourcing manufacturing and trial execution turns a large fixed capital commitment into a variable cost tied to the pace of the program, and it lets a small biotech access world-class manufacturing and trial-running expertise without spending years building it internally. That matters enormously for a company burning cash toward its next clinical catalyst, since every dollar not spent on plant construction or in-house trial staff is a dollar of runway extended.

For an investor or an acquirer, the appeal is a different but related idea: contracted revenue without molecule risk. A CDMO gets paid for the batches it manufactures and a CRO gets paid for the trial work it performs, regardless of whether the underlying drug candidate ultimately succeeds or fails in the clinic. That's a fundamentally different risk profile from owning the molecule itself, where a single failed trial can erase most of a company's value overnight.

A pharma services company isn't immune to the sector's risk entirely, since its growth still depends on how much its sponsor customers are spending on research and development in aggregate, and a broad slowdown in biopharma funding shows up eventually as softer bookings and utilization across the services base. But that's a funding-cycle exposure, not a binary clinical-trial exposure, and the distinction is exactly what a sponsor or a buyer is paying for when it chooses a services business over a pipeline asset.

How the valuation framing differs from biopharma

Because pharma services revenue is contracted and fee-based rather than tied to an approved drug's eventual sales, it doesn't get valued with biopharma's risk-adjusted net present value approach at all, a distinction covered in full in how biotech companies are valued. Instead, the sub-sector uses the same core toolkit as any EBITDA-positive services business: EV/EBITDA as the primary multiple, cross-checked against trading comps and precedent transactions.

Where it differs from a generic services business is in what specifically drives the multiple. Backlog quality matters, meaning how much contracted future work is already on the books and how firm those commitments actually are. Utilization matters, since a CDMO's manufacturing capacity or a CRO's site network only earns a return once it's actually running programs, and idle capacity is a direct drag on margin. Customer concentration matters more here than in most services businesses, since a CDMO overly dependent on manufacturing for one sponsor's flagship program carries real revenue-cliff risk if that program is discontinued or moved elsewhere. And biologics exposure specifically tends to command a premium within the sub-sector, since biologics manufacturing is more technically demanding and harder for a sponsor to bring in-house than small-molecule manufacturing, which gives the specialized CDMO more durable pricing power.

A useful way to frame this for an interviewer: pharma services typically commands a higher multiple than commodity contract manufacturing in other industries, because its customer relationships are technical, regulatory, and quality-driven rather than purely price-driven, but it trades at a discount to what a high-growth, differentiated biopharma name can command, because it doesn't carry the same blue-sky upside a successful drug launch provides. Any specific multiple mentioned in an interview should be treated as an illustrative anchor for that conversation rather than a live market quote, since actual pricing moves with backlog, biologics mix, and capacity utilization at a given point in the cycle.

A summary table

Practice question

Why would an investor prefer to own a CDMO or CRO instead of the biopharma company it serves?

Because the two businesses carry fundamentally different kinds of risk even though they both sit inside the drug-development chain. The biopharma company's value depends on whether its specific molecule succeeds through clinical trials and regulatory approval, a binary, science-driven risk that a risk-adjusted valuation tries to price but can never fully resolve until the trial reads out.

A CDMO or CRO gets paid for the manufacturing or trial work it performs on behalf of that sponsor, regardless of whether the molecule itself ultimately succeeds, so its revenue is contracted and fee-based rather than tied to one asset's binary outcome. That's why it's valued on a conventional EV/EBITDA basis rather than a pipeline-style risk-adjusted approach.

The tradeoff is that a services business doesn't capture the enormous upside a successful drug launch can create for the sponsor that owns the molecule, and it still carries real exposure to the broader biopharma funding cycle, since a slowdown in sponsor research spending eventually shows up as softer bookings and utilization across the services base. It's a lower-risk, lower-upside way to have exposure to the same underlying drug-development activity.

What the interviewer is listening for: whether you can articulate the contracted-revenue-versus-molecule-risk distinction clearly, and whether you understand that pharma services still carries a real, if different, form of sector risk rather than being entirely insulated from biopharma's ups and downs.